Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Batefenterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 20/20 | 1.00 |
| ▸ | CHRM3 known ✓ | P20309 | 20/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Batefenterol SCHEMBL384466 | 1.00 | ADRB2 (1.00) | ADRB2CHRM3CHRM2 | |
| Batefenterol SCHEMBL385358 | 1.00 | ADRB2 (1.00) | ADRB2CHRM3CHRM2 | |
| Batefenterol SCHEMBL29372665 | 1.00 | ADRB2 (1.00) | ADRB2CHRM3CHRM2 | |
| Batefenterol SCHEMBL30299015 | 1.00 | ADRB2 (1.00) | ADRB2CHRM3CHRM2 | |
| Batefenterol SCHEMBL1999609 | 0.98 | ADRB2 (0.97) | ADRB2CHRM3CHRM2 | |
| Batefenterol SCHEMBL29380164 | 0.98 | ADRB2 (0.97) | ADRB2CHRM3CHRM2 | |
| Batefenterol SCHEMBL380875 | 0.96 | ADRB2 (0.93) | ADRB2CHRM3CHRM2 | |
| SCHEMBL19173093 | 0.94 | ADRB2 (0.90) | ADRB2CHRM3CHRM2 | |
| SCHEMBL741252 | 0.94 | CHRM3 (1.00) | ADRB2CHRM3CHRM2 | |
| SCHEMBL827897 | 0.94 | ADRB2 (0.88) | ADRB2CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180256561-A1 | Pharmaceutical Combination | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-09-13 | — | — | US | claimed |
| EP-1981872-B1 | SUCCINIC ACID SALT OF BIPHENYL-2-YLCARBAMIC ACID 1-[2-(2-CHLORO-4-{[ (R)-2-HYDROXY-2- (8-HYDROXY-2-OXO-1, 2-DIHYDROQUINOLIN-5-YL) ETH YLAMINOIMETHYL]} -5-METHOXYPHENYLCARBAMOYL) ETHYL]PIPERIDIN-4-YL ESTER AND ITS USE FOR THE TREATMENT OF PULMONARY DISORDERS | GLAXO GROUP LTD (GB) | 2017-06-21 | — | — | EP | claimed |
| US-8754223-B2 | Crystalline form of a biphenyl compound | THERAVANCE, INC. (US) | 2014-06-17 | — | — | US | claimed |
| US-20130289281-A1 | CRYSTALLINE FORM OF A BIPHENYL COMPOUND | THERAVANCE, INC. (US) | 2013-10-31 | — | — | US | claimed |
| US-8476299-B2 | Crystalline form of a biphenyl compound | THERAVANCE, INC. (US) | 2013-07-02 | — | — | US | claimed |
| EP-1778672-B1 | Crystalline form of a biphenyl compound | THERAVANCE INC (US) | 2012-12-19 | — | — | EP | claimed |
| US-20120283289-A1 | CRYSTALLINE FORM OF A BIPHENYL COMPOUND | THERAVANCE, INC. (US) | 2012-11-08 | — | — | US | claimed |
| US-8101766-B2 | Crystalline form of a biphenyl compound | THERAVANCE, INC. (US) | 2012-01-24 | — | — | US | claimed |
| US-7960551-B2 | Compound | GLAXO GROUP LIMITED (GB) | 2011-06-14 | — | — | US | claimed |
| EP-1615889-B1 | BIPHENYL DERIVATIVES HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC (US) | 2010-09-29 | — | — | EP | claimed |
| US-20070281971-A1 | Novel Compound | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | claimed |
| US-20070208176-A1 | Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-06 | — | — | US | claimed |
| WO-2007090859-A1 | SUCCINIC ACID SALT OF BIPHENYL-2-YLCARBAMIC ACID 1-[2-(2-CHLORO-4-{ [ (R)-2-HYDROXY-2- (8-HYDROXY-2-OXO-1, 2-DIHYDROQUINOLIN-5-YL) ETH YLAMINOIMETHYL] } -5-METHOXYPHENYLCARBAMOYL) ETHYL] PIPERIDIN-4-YL ESTER AND ITS USE FOR THE TREATMENT OF PULMONARY DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | WO | claimed |
| EP-1778672-A1 | CRYSTALLINE FORM OF A BIPHENYL COMPOUND | Theravance, Inc. (US) | 2007-05-02 | — | — | EP | claimed |
| US-7141671-B2 | Chronic obstructive pulmonary dusease; asthma | THERAVANCE, INC. (US) | 2006-11-28 | — | — | US | claimed |
| US-20060229334-A1 | Biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenyl-carbamoyl)ethyl]piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-10-12 | — | — | US | claimed |
| WO-2006023454-A1 | CRYSTALLINE FORM OF A BIPHENYL COMPOUND | THERAVANCE, INC. (US) | 2006-03-02 | — | — | WO | claimed |
| US-20060035931-A1 | Crystalline form of a biphenyl compound | THERAVANCE, INC. | 2006-02-16 | — | — | US | claimed |
| WO-2005080375-A1 | CRYSTALLINE FORM OF A BIPHENYL COMPOUND | THERAVANCE, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-08-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035931-A1 | Crystalline form of a biphenyl compound | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ALK, PKD2 | ADRB2 1162/4885CHRM3 1116/4885CHRM2 1039/4885 |
| US-20130289281-A1 | CRYSTALLINE FORM OF A BIPHENYL COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ALK, PKD2 | ADRB2 1162/4885CHRM3 1116/4885CHRM2 1039/4885 |
| US-20120283289-A1 | CRYSTALLINE FORM OF A BIPHENYL COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ALK, PKD2 | ADRB2 1162/4885CHRM3 1116/4885CHRM2 1039/4885 |
| US-20070208176-A1 | Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma | ADRB2, ADRA2B, ADRB1 | ADRB2 1/4885CHRM3 24/4885CHRM2 12/4885 |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | ADRB1, ADRB2, ADRA2B | ADRB2 2/4885CHRM3 17/4885CHRM2 16/4885 |
| US-20060229334-A1 | Biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenyl-carbamoyl)ethyl]piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, asthma | ADRB2, ADRA2B, ADRB1 | ADRB2 1/4885CHRM3 22/4885CHRM2 9/4885 |
| US-20180256561-A1 | Pharmaceutical Combination | IL5, CYP11B2, HSD11B2 | ADRB2 34/4885CHRM3 134/4885CHRM2 168/4885 |
| US-20070281971-A1 | Novel Compound | SUCNR1, SLC16A7, SLC16A1 | ADRB2 1963/4885CHRM3 3178/4885CHRM2 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.